Publications by authors named "I V Khromova"
Hypersensitivity reaction (HSR) and hepatotoxicity are rare, but potentially serious side-effects of antiretroviral use. To investigate discontinuations due to HSR, hepatotoxicity or other reasons among users of dolutegravir (DTG) vs. raltegravir (RAL) or elvitegravir (EVG) in the EuroSIDA cohort.
View Article and Find Full Text PDFObjective: To evaluate time trends in pregnancies and pregnancy outcomes among women with HIV in Europe.
Design: European multicentre prospective cohort study.
Methods: EuroSIDA has collected annual cross-sectional audits of pregnancies between 1996 and 2015.
Article Synopsis
- The study investigates the impact of hepatitis C virus (HCV) coinfection and HCV-RNA levels on the development of diabetes mellitus (DM) in individuals with HIV.
- Using Poisson regression, researchers analyzed data from over 16,099 HIV-positive participants, examining various HCV statuses, to determine DM incidence rates.
- Findings indicated no significant difference in DM development among different HCV groups; key risk factors identified were hypertension and obesity, highlighting the importance of managing these comorbidities.
Background And Aims: To investigate the uptake of hepatitis C virus (HCV) therapy among HIV/HCV-coinfected patients in the pan-European EuroSIDA study between 2011 and 2016.
Methods: All HCV-RNA+ patients were included. Baseline was defined as latest of anti-HCV+, January 2011 or enrolment in EuroSIDA.
Objectives: The aim of the study was to evaluate the long-term response to antiretroviral treatment (ART) based on atazanavir/ritonavir (ATZ/r)-, darunavir/ritonavir (DRV/r)-, and lopinavir/ritonavir (LPV/r)-containing regimens.
Methods: Data were analysed for 5678 EuroSIDA-enrolled patients starting a DRV/r-, ATZ/r- or LPV/r-containing regimen between 1 January 2000 and 30 June 2013. Separate analyses were performed for the following subgroups of patients: (1) ART-naïve subjects (8%) at ritonavir-boosted protease inhibitor (PI/r) initiation; (2) ART-experienced individuals (44%) initiating the new PI/r with a viral load (VL) ≤500 HIV-1 RNA copies/mL; and (3) ART-experienced patients (48%) initiating the new PI/r with a VL >500 copies/mL.